166 related articles for article (PubMed ID: 17645292)
1. Doxorubicin cardiotoxicity in the rat: an in vivo characterization.
Hayward R; Hydock DS
J Am Assoc Lab Anim Sci; 2007 Jul; 46(4):20-32. PubMed ID: 17645292
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the effect of in vivo doxorubicin treatment on skeletal muscle function in the rat.
Hydock DS; Lien CY; Jensen BT; Schneider CM; Hayward R
Anticancer Res; 2011 Jun; 31(6):2023-8. PubMed ID: 21737618
[TBL] [Abstract][Full Text] [Related]
3. Time course of cardiomyopathy induced by doxorubicin in rats.
Medeiros-Lima DJM; Carvalho JJ; Tibirica E; Borges JP; Matsuura C
Pharmacol Rep; 2019 Aug; 71(4):583-590. PubMed ID: 31174019
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress on cardiotoxicity after treatment with single and multiple doses of doxorubicin.
Segredo MP; Salvadori DM; Rocha NS; Moretto FC; Correa CR; Camargo EA; de Almeida DC; Reis RA; Freire CM; Braz MG; Tang G; Matsubara LS; Matsubara BB; Yeum KJ; Ferreira AL
Hum Exp Toxicol; 2014 Jul; 33(7):748-60. PubMed ID: 24275640
[TBL] [Abstract][Full Text] [Related]
5. Protective effects of mito-TEMPO against doxorubicin cardiotoxicity in mice.
Rocha VC; França LS; de Araújo CF; Ng AM; de Andrade CM; Andrade AC; Santos Ede S; Borges-Silva Mda C; Macambira SG; Noronha-Dutra AA; Pontes-de-Carvalho LC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):659-62. PubMed ID: 26712129
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
7. Scutellarin protects against doxorubicin-induced acute cardiotoxicity and regulates its accumulation in the heart.
Sun XP; Wan LL; Yang QJ; Huo Y; Han YL; Guo C
Arch Pharm Res; 2017 Jul; 40(7):875-883. PubMed ID: 28315259
[TBL] [Abstract][Full Text] [Related]
8. Acute exercise protects against doxorubicin cardiotoxicity.
Wonders KY; Hydock DS; Schneider CM; Hayward R
Integr Cancer Ther; 2008 Sep; 7(3):147-54. PubMed ID: 18815146
[TBL] [Abstract][Full Text] [Related]
9. Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction.
Hydock DS; Lien CY; Schneider CM; Hayward R
Med Sci Sports Exerc; 2008 May; 40(5):808-17. PubMed ID: 18408619
[TBL] [Abstract][Full Text] [Related]
10. Loss of multidrug resistance-associated protein 1 potentiates chronic doxorubicin-induced cardiac dysfunction in mice.
Zhang W; Deng J; Sunkara M; Morris AJ; Wang C; St Clair D; Vore M
J Pharmacol Exp Ther; 2015 Nov; 355(2):280-7. PubMed ID: 26354995
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats.
Fadillioglu E; Oztas E; Erdogan H; Yagmurca M; Sogut S; Ucar M; Irmak MK
J Appl Toxicol; 2004; 24(1):47-52. PubMed ID: 14745846
[TBL] [Abstract][Full Text] [Related]
12. Ultrastructural and Echocardiographic Assessment of Chronic Doxorubicin-Induced Cardiotoxicity in Rats.
Babaei H; Razmaraii N; Assadnassab G; Mohajjel Nayebi A; Azarmi Y; Mohammadnejad D; Azami A
Arch Razi Inst; 2020 Mar; 75(1):55-62. PubMed ID: 32292003
[TBL] [Abstract][Full Text] [Related]
13. Switching to a low-fat diet attenuates the intensified doxorubicin cardiotoxicity associated with high-fat feeding.
Hydock DS; Lien CY; Jensen BT; Schneider CM; Hayward R
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1551-60. PubMed ID: 23568281
[TBL] [Abstract][Full Text] [Related]
14. Modification of doxorubicin-induced cardiotoxicity: manipulation of the dosage schedule.
Yeung TK; Chakrabarti K; Wilding D; Hopewell JW
Hum Exp Toxicol; 2002 Nov; 21(11):607-14. PubMed ID: 12507256
[TBL] [Abstract][Full Text] [Related]
15. Exercise preconditioning provides long-term protection against early chronic doxorubicin cardiotoxicity.
Hydock DS; Lien CY; Jensen BT; Schneider CM; Hayward R
Integr Cancer Ther; 2011 Mar; 10(1):47-57. PubMed ID: 21382960
[TBL] [Abstract][Full Text] [Related]
16. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
Working PK; Newman MS; Sullivan T; Yarrington J
J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
[TBL] [Abstract][Full Text] [Related]
17. Rehabilitative exercise in a rat model of doxorubicin cardiotoxicity.
Hydock DS; Lien CY; Jensen BT; Parry TL; Schneider CM; Hayward R
Exp Biol Med (Maywood); 2012 Dec; 237(12):1483-92. PubMed ID: 23354407
[TBL] [Abstract][Full Text] [Related]
18. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
[TBL] [Abstract][Full Text] [Related]
19. Exercise mitigates cardiac doxorubicin accumulation and preserves function in the rat.
Jensen BT; Lien CY; Hydock DS; Schneider CM; Hayward R
J Cardiovasc Pharmacol; 2013 Sep; 62(3):263-9. PubMed ID: 23644988
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent.
Hopewel JW; Duncan R; Wilding D; Chakrabarti K
Hum Exp Toxicol; 2001 Sep; 20(9):461-70. PubMed ID: 11776408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
